# Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

> **NCT06959511** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 45 (estimated)

## Conditions studied

- Neoadjuvant Treatment
- Thyroid Cancer

## Interventions

- **DRUG:** Zanzalintinib

## Key facts

- **NCT ID:** NCT06959511
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-22
- **Primary completion:** 2028-03-01
- **Final completion:** 2030-10-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06959511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06959511, "Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06959511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*